May 5, 2025 03:59 PM EDT
R&D

PTC's Hunt­ing­ton’s study suc­ceeds, but ac­cel­er­at­ed ap­proval un­cer­tain

Lei Lei Wu

News Reporter

PTC Ther­a­peu­tics an­nounced Mon­day that its splic­ing drug for Hunt­ing­ton’s dis­ease met the pri­ma­ry end­point of a Phase 2 study, but …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Trump ad­min­is­tra­tion halts more than $750M in funds for Mod­er­na’s bird flu vac­cine

A new dawn for psy­che­delics? Com­pass could be the first to find out

The fate of Mod­er­na’s next-gen Covid shot looms large af­ter a flur­ry of pol­i­cy changes

Up­dat­ed: MD An­der­son-al­lied in­vest­ment firm tar­gets $250M for sec­ond can­cer biotech fund

Weeks af­ter TIG­IT fail, iTeos de­cides to wind down

sponsored

From weeks to days: how Aizon In­tel­li­gent Agents trans­form phar­ma val­i­da­tion

A service from the Financial Times